VRTX
Vertex Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
6.12 / 10
Outperform
Capital flow assessment yields 7.73/10, denoting robust fund flow characteristics. Strengths in Small, Medium, and Large trends confront pressures from overall, block, and Extra-large patterns, resulting in positive liquidity outlook. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(20.0%), Buy(80.0%) across 5 coverage providers, supported by 4.50 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
20%
Buy
80%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-22
InstitutionRBC Capital
Times predicted8
Historical Win Rate87.5%
Is money flowing into or out of VRTX?
- VRTX holds a Bearish analyst rating, with 80% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.12/10 (Outperform).
